Study of the Cardiometabolic Effects of Obesity Pharmacotherapy

NCT04575194 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Obesity
Blood Pressure

Interventions

DRUG: Liraglutide 6 MG/ML [Saxenda]
DRUG: Naltrexone-Bupropion Combination

Sponsor

National and Kapodistrian University of Athens

Collaborators

[object Object]